160.05 USD
-3.58 (-2.19%)
160.05 USD
0 (0%)
Overall RGEN gets a fundamental rating of 5 out of 10. We evaluated RGEN against 58 industry peers in the Life Sciences Tools & Services industry. While RGEN has a great health rating, its profitability is only average at the moment. RGEN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year RGEN was profitable.
- RGEN had a positive operating cash flow in the past year.
- RGEN had positive earnings in 4 of the past 5 years.
- In the past 5 years RGEN always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.06%, RGEN is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
- Looking at the Return On Equity, with a value of 0.08%, RGEN is in the better half of the industry, outperforming 70.69% of the companies in the same industry.
- With a Return On Invested Capital value of 1.05%, RGEN perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for RGEN is significantly below the industry average of 13.29%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.06% | ||
| ROE | 0.08% | ||
| ROIC | 1.05% |
ROA(3y)2.57%
ROA(5y)3.26%
ROE(3y)3.42%
ROE(5y)4.3%
ROIC(3y)2.65%
ROIC(5y)3.3%
1.3 Margins
- The Profit Margin of RGEN (0.25%) is better than 68.97% of its industry peers.
- RGEN's Operating Margin of 6.58% is fine compared to the rest of the industry. RGEN outperforms 62.07% of its industry peers.
- RGEN's Operating Margin has declined in the last couple of years.
- The Gross Margin of RGEN (51.59%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of RGEN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.58% | ||
| PM (TTM) | 0.25% | ||
| GM | 51.59% |
OM growth 3Y-58.46%
OM growth 5Y-32.3%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.88%
GM growth 5Y-2.12%
2. Health
2.1 Basic Checks
- RGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- RGEN has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for RGEN has been increased compared to 5 years ago.
- RGEN has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 7.33 indicates that RGEN is not in any danger for bankruptcy at the moment.
- With an excellent Altman-Z score value of 7.33, RGEN belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
- The Debt to FCF ratio of RGEN is 5.05, which is a neutral value as it means it would take RGEN, 5.05 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 5.05, RGEN is doing good in the industry, outperforming 67.24% of the companies in the same industry.
- RGEN has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
- RGEN has a Debt to Equity ratio of 0.26. This is comparable to the rest of the industry: RGEN outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 5.05 | ||
| Altman-Z | 7.33 |
ROIC/WACC0.1
WACC10.73%
2.3 Liquidity
- RGEN has a Current Ratio of 8.36. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
- RGEN has a better Current ratio (8.36) than 91.38% of its industry peers.
- RGEN has a Quick Ratio of 7.14. This indicates that RGEN is financially healthy and has no problem in meeting its short term obligations.
- RGEN has a better Quick ratio (7.14) than 89.66% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.36 | ||
| Quick Ratio | 7.14 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 21.17% over the past year.
- Measured over the past 5 years, RGEN shows a small growth in Earnings Per Share. The EPS has been growing by 7.11% on average per year.
- Looking at the last year, RGEN shows a decrease in Revenue. The Revenue has decreased by -8.54% in the last year.
- The Revenue has been growing by 18.62% on average over the past years. This is quite good.
EPS 1Y (TTM)21.17%
EPS 3Y-21.5%
EPS 5Y7.11%
EPS Q2Q%6.98%
Revenue 1Y (TTM)-8.54%
Revenue growth 3Y-1.83%
Revenue growth 5Y18.62%
Sales Q2Q%21.94%
3.2 Future
- The Earnings Per Share is expected to grow by 24.54% on average over the next years. This is a very strong growth
- Based on estimates for the next years, RGEN will show a quite strong growth in Revenue. The Revenue will grow by 15.92% on average per year.
EPS Next Y14.84%
EPS Next 2Y19.33%
EPS Next 3Y22.24%
EPS Next 5Y24.54%
Revenue Next Year15.61%
Revenue Next 2Y14.01%
Revenue Next 3Y14.31%
Revenue Next 5Y15.92%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 96.42, the valuation of RGEN can be described as expensive.
- The rest of the industry has a similar Price/Earnings ratio as RGEN.
- When comparing the Price/Earnings ratio of RGEN to the average of the S&P500 Index (28.60), we can say RGEN is valued expensively.
- With a Price/Forward Earnings ratio of 75.94, RGEN can be considered very expensive at the moment.
- The rest of the industry has a similar Price/Forward Earnings ratio as RGEN.
- The average S&P500 Price/Forward Earnings ratio is at 25.83. RGEN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96.42 | ||
| Fwd PE | 75.94 |
4.2 Price Multiples
- RGEN's Enterprise Value to EBITDA is on the same level as the industry average.
- The rest of the industry has a similar Price/Free Cash Flow ratio as RGEN.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 84.61 | ||
| EV/EBITDA | 79.29 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates RGEN does not grow enough to justify the current Price/Earnings ratio.
- A more expensive valuation may be justified as RGEN's earnings are expected to grow with 22.24% in the coming years.
PEG (NY)6.5
PEG (5Y)13.57
EPS Next 2Y19.33%
EPS Next 3Y22.24%
5. Dividend
5.1 Amount
- No dividends for RGEN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
REPLIGEN CORP / RGEN FAQ
Can you provide the ChartMill fundamental rating for REPLIGEN CORP?
ChartMill assigns a fundamental rating of 5 / 10 to RGEN.
What is the valuation status for RGEN stock?
ChartMill assigns a valuation rating of 2 / 10 to REPLIGEN CORP (RGEN). This can be considered as Overvalued.
What is the profitability of RGEN stock?
REPLIGEN CORP (RGEN) has a profitability rating of 4 / 10.
What is the financial health of REPLIGEN CORP (RGEN) stock?
The financial health rating of REPLIGEN CORP (RGEN) is 7 / 10.
What is the earnings growth outlook for REPLIGEN CORP?
The Earnings per Share (EPS) of REPLIGEN CORP (RGEN) is expected to grow by 14.84% in the next year.